ft 21 jul 92 glaxo focu aid drug glaxo uk pharmaceut group pour million pound prioriti develop programm candid aid drug 3tc compani scientist hope drug emerg clinic trial first commerci success altern wellcom azt drug retrovir first result trial due week intern aid confer amsterdam although 180 patient taken 3tc month studi show drug reduc impact hiv viru caus aid 3tc prevent hiv replic way azt two recent approv similar drug ddi bristol myer squibb ddc roch howev 3tc avoid interact human cell caus toxic side effect drug statement amsterdam yesterday glaxo tri arous prematur expect among aid patient glaxo said develop 3tc highest prioriti earli sure ultim role compound treatment hiv infect share close london 10p 688p wellcom 25p 845p weak market aid confer also like bring posit news wellcom azt aid drug come investor make final decis wellcom pound 2 65bn global share offer close friday glaxo develop 3tc biochem pharma canadian compani discov dr gervai dionn research vice presid biochem pharma said plan move larg scale clinic trial 1993 also give good result glaxo appli market licenc 1994 glaxo devot substanti resourc 3tc said dr grahaem brown charg develop programm noth allow stand way glaxo prepar heavi demand 3tc drug receiv market approv hiv infect still increas rapidli worldwid altern azt give encourag result sale 3tc could worth sever hundr million dollar year glaxo late 1990 market page 34